NOV 14, 2018 6:00 AM PST

Improving Sepsis Management with Same-Day Results from the Lab

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • President and CEO, T2 Biosystems
    Biography
      At the helm of T2 Biosystems, Mr. McDonough and his team took a new technology concept from MIT and MGH and grew it into a publicly-traded company that has the first and only FDA-cleared diagnostic products to directly detect sepsis-causing pathogens in blood. T2Direct Diagnostics™ are improving patient care in over 160 hospitals worldwide - helping patients with potentially life-threatening illness receive targeted treatment as much as eight times faster.

    Abstract

    Sepsis is the Achilles’ heel of health care. Despite being relatively unknown to the public, it is a top killer in hospitals and the cost burden is crushing to our healthcare system. More and more, sepsis is keeping hospital CFO’s up at night and is the focus of widespread hospital initiatives. And labs play a critical role in providing a solution that provides return on investment for hospitals and improves patient care.

    Hospitals’ top defense against sepsis today is empiric therapy, a probability based approach with broad-spectrum antibiotic care in the absence of species-specific information about the cause of a patient’s infection (if they have an infection at all). Despite the successes of empiric therapy, it is still severely limited by lack of actionable diagnostic information, with studies demonstrating that up to 40% of bloodstream infections receive incorrect treatment.

    In this talk, entrepreneur and CEO John McDonough will share how lab implementation of rapid diagnostics can significantly improve empiric therapy, reduce costs, and potentially save lives. New tests now available in over 160 hospitals worldwide allow for more targeted empiric therapy, improving patient outcomes and driving down hospital costs through reduced length of stay and pharmacy costs. Mr. McDonough will present on the breakthrough T2Bacteria and T2Candida Panels, the first FDA-cleared tests to directly provide species-specific results for sepsis-causing pathogens in 3 to 5 hours, without the wait for blood culture. 

     
    Learning Objectives: 

    1. Review the efficacy of empiric therapy for patients at risk of sepsis and blood stream infections
    2. Describe the limitations of current sepsis management
    3. Review T2MR technology for rapid identification of bacterial pathogens
    4. Describe ability for breakthrough diagnostic technology to improve empiric therapy and provide faster, targeted therapy 


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees
    • See more